$CRIS
CURIS INC

2024 Q4 Form 10-Q Financial Statement

#000110820524000072 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $2.931M
YoY Change 3.46%
Cost Of Revenue $22.00K
YoY Change -63.33%
Gross Profit $2.909M
YoY Change 5.02%
Gross Profit Margin 99.25%
Selling, General & Admin $3.753M
YoY Change -21.16%
% of Gross Profit 129.01%
Research & Development $9.723M
YoY Change -6.33%
% of Gross Profit 334.24%
Depreciation & Amortization $61.00K
YoY Change 1.67%
% of Gross Profit 2.1%
Operating Expenses $9.723M
YoY Change -6.33%
Operating Profit -$10.57M
YoY Change -14.56%
Interest Expense $325.0K
YoY Change -59.88%
% of Operating Profit
Other Income/Expense, Net $475.0K
YoY Change 154.01%
Pretax Income -$10.09M
YoY Change -17.14%
Income Tax
% Of Pretax Income
Net Earnings -$10.09M
YoY Change -17.15%
Net Earnings / Revenue -344.32%
Basic Earnings Per Share -$1.70
Diluted Earnings Per Share -$1.70
COMMON SHARES
Basic Shares Outstanding 8.467M shares 5.979M shares
Diluted Shares Outstanding 5.941M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.85M
YoY Change -69.56%
Cash & Equivalents $20.00M $20.85M
Short-Term Investments $0.00
Other Short-Term Assets $3.105M
YoY Change 47.86%
Inventory
Prepaid Expenses
Receivables $3.349M $2.978M
Other Receivables $0.00
Total Short-Term Assets $26.39M $26.94M
YoY Change -56.68% -63.31%
LONG-TERM ASSETS
Property, Plant & Equipment $231.0K $246.0K
YoY Change -46.77% -50.5%
Goodwill $9.000M $8.982M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.960M $2.303M
YoY Change -41.63% -26.28%
Total Long-Term Assets $14.88M $15.54M
YoY Change -9.12% -6.12%
TOTAL ASSETS
Total Short-Term Assets $26.39M $26.94M
Total Long-Term Assets $14.88M $15.54M
Total Assets $41.27M $42.47M
YoY Change -46.6% -52.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.024M $3.818M
YoY Change -4.67% -26.87%
Accrued Expenses $7.111M $8.141M
YoY Change -21.34% 12.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $7.556M
YoY Change -11.15%
Total Short-Term Liabilities $19.03M $22.03M
YoY Change 40.76% 60.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $29.17M
YoY Change -37.53%
Total Long-Term Liabilities $29.17M
YoY Change -37.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.03M $22.03M
Total Long-Term Liabilities $29.17M
Total Liabilities $47.26M $51.21M
YoY Change -17.96% -15.2%
SHAREHOLDERS EQUITY
Retained Earnings -$1.200B -$1.200B
YoY Change 0.0% 0.0%
Common Stock $1.234B $1.221B
YoY Change 1.48% 0.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.998M -$8.735M
YoY Change
Total Liabilities & Shareholders Equity $41.27M $42.47M
YoY Change -46.6% -52.79%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$10.09M
YoY Change -17.15%
Depreciation, Depletion And Amortization $61.00K
YoY Change 1.67%
Cash From Operating Activities -$5.936M
YoY Change -27.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $18.32M
YoY Change 10076.67%
Cash From Investing Activities $18.32M
YoY Change 10076.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.524M
YoY Change -112.13%
NET CHANGE
Cash From Operating Activities -5.936M
Cash From Investing Activities 18.32M
Cash From Financing Activities -1.524M
Net Change In Cash 10.86M
YoY Change 138.11%
FREE CASH FLOW
Cash From Operating Activities -$5.936M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001108205
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Goodwill
Goodwill
8982000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
8982000 usd
CY2024Q3 us-gaap Assets
Assets
42473000 usd
CY2023Q4 us-gaap Assets
Assets
77282000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3818000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3172000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8141000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9040000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1292000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2833000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10380000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2931000 usd
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9723000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3753000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
13498000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
15201000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10567000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5720789 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5720789 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10092000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12181000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
101000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10134000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12080000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
128 Spring Street
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8466957 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20854000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26681000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29653000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2978000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2794000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3105000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1780000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
26937000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
544000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3461000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3056000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1305000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
475000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
187000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.70
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.70
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5940924 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5847982 shares
CY2023Q3 cris Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
619000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5847982 shares
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-296000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11803000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-694000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13999000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25012000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10092000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13770000 usd
dei Entity Address Address Line2
EntityAddressAddressLine2
Building C - Suite 500
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2303000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Registrant Name
EntityRegistrantName
CURIS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 us-gaap Assets Current
AssetsCurrent
60908000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
434000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
544000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3358000 usd
CY2024Q3 cris Royalty Guarantees Commitments Amount Current
RoyaltyGuaranteesCommitmentsAmountCurrent
8783000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22034000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22021000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1489000 usd
CY2023Q4 cris Royalty Guarantees Commitments Amount Noncurrent
RoyaltyGuaranteesCommitmentsAmountNoncurrent
34102000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
51208000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
57612000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
34171875 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
22781250 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
59000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1221386000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1230181000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1196410000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-8735000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19670000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42473000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77282000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7563000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7327000 usd
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
60000 usd
us-gaap Royalty Expense
RoyaltyExpense
158000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29594000 usd
us-gaap Costs And Expenses
CostsAndExpenses
43460000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29532000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13436000 usd
us-gaap Costs And Expenses
CostsAndExpenses
43111000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-35548000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-36133000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1541000 usd
cris Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
-236000 usd
cris Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
1841000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
432000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35701000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.77
us-gaap Net Income Loss
NetIncomeLoss
-35701000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
289000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35412000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19670000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1559000 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
109000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11876000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9462000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1704000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
806000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2273000 usd
CY2024Q3 cris Non Cash Imputed Interest Expense
NonCashImputedInterestExpense
-150000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1777000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33771000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-229000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
78000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3505116
CY2023Q4 cris Royalty Guarantees Commitments Amount Current
RoyaltyGuaranteesCommitmentsAmountCurrent
8504000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1968000 usd
CY2024Q3 cris Royalty Guarantees Commitments Amount Noncurrent
RoyaltyGuaranteesCommitmentsAmountNoncurrent
27206000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6020259 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6020259 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5894085 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5894085 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
60000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1215792000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
229000 usd
CY2024Q3 us-gaap Royalty Expense
RoyaltyExpense
22000 usd
us-gaap Royalty Expense
RoyaltyExpense
81000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4761000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12368000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
325000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33771000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.96
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5131904 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5131904 shares
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1384000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
709000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0 usd
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-42000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-8735000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46552000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1395000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
195000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11559000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
36591000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1424000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
178000 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-7000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11961000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
26225000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13814000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1633000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1000 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
101000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-12181000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
29591000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33771000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35701000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
187000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
191000 usd
cris Non Cash Lease Expense
NonCashLeaseExpense
978000 usd
cris Non Cash Lease Expense
NonCashLeaseExpense
999000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4647000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4452000 usd
cris Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
-236000 usd
cris Non Cash Imputed Interest Expense Net Of Imputed Interest
NonCashImputedInterestExpenseNetOfImputedInterest
-336000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
444000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1044000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
184000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-127000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
270000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-338000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-293000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3574000 usd
cris Increase Decrease Operating Lease Liability
IncreaseDecreaseOperatingLeaseLiability
-917000 usd
cris Increase Decrease Operating Lease Liability
IncreaseDecreaseOperatingLeaseLiability
-848000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3468000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
7453000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30303000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28248000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
18098000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
64656000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
47968000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
87925000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29870000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23269000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
987000 usd
cris Payments Of Future Royalty Liability
PaymentsOfFutureRoyaltyLiability
6381000 usd
cris Payments Of Future Royalty Liability
PaymentsOfFutureRoyaltyLiability
4301000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5394000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9698000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5827000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4719000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27225000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20293000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21398000 usd
CY2024Q3 cris Accrued Issuance Costs
AccruedIssuanceCosts
40000 usd
CY2023Q3 cris Accrued Issuance Costs
AccruedIssuanceCosts
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
2177000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1383000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20854000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24468000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
544000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
544000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21398000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25012000 usd
us-gaap Nature Of Operations
NatureOfOperations
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Nature of Business</span><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as the “Company” or “Curis”.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration agreement with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, including emavusertib.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to continue as a going concern; the Company’s ability to advance and expand its research and development program for emavusertib; the Company’s ability to execute on its overall business strategies; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company’s ability to obtain and maintain applicable regulatory approvals and commercialize any approved drug candidates; and the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”), to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with TPC Investments I LP and TPC Investments II LP (the “Purchasers”), each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC (the “Agent”), a Delaware limited liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of emavusertib and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain its research and development programs and support operations. The Company has incurred losses and cash outflows from operations since its inception. The Company had an accumulated deficit of $1.2 billion as of September 30, 2024, and incurred a net loss of $33.8 million and used $30.3 million of cash in operations for the nine months ended September 30, 2024. The Company expects to continue to generate operating losses in the foreseeable future. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. Based on the Company's $20.9 million of existing cash and cash equivalents at September 30, 2024, the net proceeds of approximately $10.8 million from the October 2024 Offerings discussed below in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these Notes to the Condensed Consolidated Financial Statements, recurring losses and cash outflows from operations since inception, an expectation of continuing losses and cash outflows from operations for the foreseeable future and the need to raise additional capital to finance the Company's future operations, the Company concluded it does not have sufficient cash on hand to support current operations for the next 12 months from the date of filing this Quarterly Report on Form 10-Q. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to seek additional funding through a number of potential avenues, including private or public equity financings, collaborations, or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate its development of emavusertib, potentially delaying the time to market for or preventing the marketing of emavusertib, which may have a material adverse effect on the Company’s operations and future prospects.</span></div>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1200000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30300000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
20900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.84pt">Use of Estimates and Assumptions</span><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the collectability of receivables; and the value of certain investments and liabilities. Actual results may differ from such estimates. These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</span></div>
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
500000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
500000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29654000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29653000 usd
CY2023 cris Available For Sale Securities Weighted Average Maturity
AvailableForSaleSecuritiesWeightedAverageMaturity
P0Y2M12D
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2971000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3701000 usd
CY2024Q3 cris Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
4380000 usd
CY2023Q4 cris Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
4163000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
782000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1059000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
117000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8141000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9040000 usd
cris Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
1400000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3300000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3500000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2800000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3100000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
400000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
400000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2019Q1 cris Royalty Purchase Agreement Interest Rate
RoyaltyPurchaseAgreementInterestRate
0
CY2019Q1 cris Royalty Purchase Agreement Transaction Fees And Closing Costs
RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts
600000 usd
CY2023Q4 cris Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
42606000 usd
cris Royalty Purchase Agreement Other
RoyaltyPurchaseAgreementOther
-236000 usd
cris Payments Of Future Royalty Liability
PaymentsOfFutureRoyaltyLiability
6381000 usd
CY2024Q3 cris Royalty Purchase Agreement Liability Carrying Value
RoyaltyPurchaseAgreementLiabilityCarryingValue
35989000 usd
CY2024Q3 cris Current Portion Of Future Royalty Liability
CurrentPortionOfFutureRoyaltyLiability
8783000 usd
CY2024Q3 cris Royalty Purchase Agreement Liability Current Portion
RoyaltyPurchaseAgreementLiabilityCurrentPortion
27206000 usd
CY2024Q1 cris Royalty Guarantees Commitments Amount Current
RoyaltyGuaranteesCommitmentsAmountCurrent
8793000 usd
CY2024Q1 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
31329000 usd
CY2023Q4 cris Royalty Guarantees Commitments Amount Current
RoyaltyGuaranteesCommitmentsAmountCurrent
8504000 usd
CY2023Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
34102000 usd
CY2022Q4 cris Royalty Guarantees Commitments Amount Current
RoyaltyGuaranteesCommitmentsAmountCurrent
6257000 usd
CY2022Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
43226000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
22781250 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
34171875 shares
cris Share Based Compensation Plans
ShareBasedCompensationPlans
2 plan
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
840880 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.58
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
518270 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
198899 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
45.82
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1160251 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
551464 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
55.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1160251 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
33.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.00
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1384000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1633000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4647000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4452000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001108205-24-000072-index-headers.html Edgar Link pending
0001108205-24-000072-index.html Edgar Link pending
0001108205-24-000072.txt Edgar Link pending
0001108205-24-000072-xbrl.zip Edgar Link pending
cris-20240930.htm Edgar Link pending
cris-20240930.xsd Edgar Link pending
cris-9302024x10qexx311.htm Edgar Link pending
cris-9302024x10qexx312.htm Edgar Link pending
cris-9302024x10qexx321.htm Edgar Link pending
cris-9302024x10qexx322.htm Edgar Link pending
curisandaurigene4thamendto.htm Edgar Link pending
curisandaurigeneamendno3to.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
cris-20240930_lab.xml Edgar Link unprocessable
cris-20240930_pre.xml Edgar Link unprocessable
cris-20240930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cris-20240930_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cris-20240930_cal.xml Edgar Link unprocessable